Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 642 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

642 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

642 programs

Clinical programs

Page 3 of 14

  1. KT-US-679-0788

    Lacuna Pharma Pty Ltd

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  2. KVD900, KVD900

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  3. KVD900, KVD900

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  4. LEX-210

    Lacuna Pharma Pty Ltd

    Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor

    phase 3 small molecule active

    1 trial

  5. LP352-301

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  6. LP352-302

    Lacuna Pharma Pty Ltd

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

  7. LP352-303

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  8. LTFU-ABO-102

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA

    phase 3 small molecule active

    1 trial

  9. LUM-201-10

    Lacuna Pharma Pty Ltd

    Growth Hormone Deficiency (GHD)

    phase 3 small molecule active

    1 trial

  10. Lucerastat

    Lacuna Pharma Pty Ltd

    Fabry disease

    phase 3 small molecule active

    1 trial

  11. MG0014

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  12. MG0015

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  13. MIN-003-1806

    Lacuna Pharma Pty Ltd

    Newly diagnosed primary glioblastoma multiforme (ndGBM)

    phase 3 small molecule active

    1 trial

  14. MITAPIVAT, Placebo for Mitapivat

    Lacuna Pharma Pty Ltd

    Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  15. MOG001

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  16. MRX-802

    Lacuna Pharma Pty Ltd

    Cholestatic Pruritus

    phase 3 small molecule active

    1 trial

  17. MT-7117 Formulation Code C

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

    phase 3 small molecule active

    1 trial

  18. MT-7117 Formulation Code C, MT-7117 Placebo

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria or X-Linked Protoporphyria

    phase 3 small molecule active

    1 trial

  19. MaaT013

    Lacuna Pharma Pty Ltd

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

  20. N01269

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  21. NOE-TGN-201

    Lacuna Pharma Pty Ltd

    Trigeminal neuralgia, Trigeminal neuralgia

    phase 3 small molecule active

    1 trial

  22. NOPRODPAPUH3001

    Lacuna Pharma Pty Ltd

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  23. NORADRENALINA TARTRATO MONICO 2 mg/ml Concentrato per soluzione per infusione

    Lacuna Pharma Pty Ltd

    criticall illness

    phase 3 small molecule active

    1 trial

  24. NW-3509/023/III/2024

    Lacuna Pharma Pty Ltd

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  25. OBEZ-302

    Lacuna Pharma Pty Ltd

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  26. OBEZ-303

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  27. OBI-822-011

    Lacuna Pharma Pty Ltd

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  28. OCA 5MG IR +BZF 400 MG SR

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  29. ONO-4059-17

    Lacuna Pharma Pty Ltd

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  30. OP-LIPC02

    Lacuna Pharma Pty Ltd

    Recurrent herpes labialis (RHL)

    phase 3 small molecule active

    1 trial

  31. OP0595-5

    Lacuna Pharma Pty Ltd

    Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  32. OP0595-6

    Lacuna Pharma Pty Ltd

    Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)

    phase 3 small molecule active

    1 trial

  33. P-Monofer-CHF-02

    Lacuna Pharma Pty Ltd

    Chronic Heart Failure

    phase 3 small molecule active

    1 trial

  34. PA0016

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  35. PANC-CAP-3001

    Lacuna Pharma Pty Ltd

    Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).

    phase 3 small molecule active

    1 trial

  36. PBP-301

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  37. PICO-TRAT

    Lacuna Pharma Pty Ltd

    Second line treatment for colonoscopy preparation

    phase 3 small molecule active

    1 trial

  38. PM1183-C-008-21

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  39. PPP001

    Lacuna Pharma Pty Ltd

    Palmoplantar Pustulosis

    phase 3 small molecule active

    1 trial

  40. PRO-RCT-ACAROS-2018

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis due to exposure of house dust mites

    phase 3 small molecule active

    1 trial

  41. PS0021

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  42. Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

    Lacuna Pharma Pty Ltd

    Acute pain

    phase 3 small molecule active

    1 trial

  43. Placebo for Mitapivat, MITAPIVAT

    Lacuna Pharma Pty Ltd

    Non–Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  44. Placebo matching AMX0035, AMX0035

    Lacuna Pharma Pty Ltd

    Progressive Supranuclear Palsy

    phase 3 small molecule active

    1 trial

  45. Placebo matching REGN7508, REGN7508

    Lacuna Pharma Pty Ltd

    Cancer-Associated Thrombosis (CAT).

    phase 3 small molecule active

    1 trial

  46. Placebo matching to garetosmab, Garetosmab

    Lacuna Pharma Pty Ltd

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  47. PolyCore

    Lacuna Pharma Pty Ltd

    Congestive Heart Failure

    phase 3 small molecule active

    1 trial

  48. Powder for reconstitution for enteral administration

    Lacuna Pharma Pty Ltd

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.